nature aging

Letter

https://doi.org/10.1038/s43587-025-01057-z

Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistance

Received: 15 October 2024

Accepted: 19 December 2025

Published online: 29 January 2026

Check for updates

Masahiro Wakita[1], Koyu Ito[1,2], Kaho Fujii[1], Dai Sakamoto[1], Takumi Mikawa[3], Sho Sugawara[4], Xiangyu Zhou[4], Jeong Hoon Park[1], Hideka Miyagawa[1], Daisuke Motooka[1], Emi Ogasawara[5], Naotada Ishihara[5], Akiko Takahashi[4,6], Hiroshi Kondoh[3] & Eiji Hara[1,7,8]

Cellular senescence contributes to aging and disease, and senolytic drugs that selectively eliminate senescent cells hold therapeutic promise. Although over 20 candidates have been reported, their relative efficacies remain unclear. Here we systematically compared 21 senolytic agents using a senolytic specificity index, identifying the Bcl-2 inhibitor ABT263 and the BET inhibitor ARV825 as most effective senolytics across fibroblast and epithelial senescence models. However, even upon extended treatment with these most potent senolytics, a proportion of senescent cells remained viable. We found that senolytic resistance was driven by maintenance of mitochondrial integrity through V-ATPase-mediated clearance of damaged mitochondria. Imposing mitochondrial stress via metabolic workload enhanced the senolytic efficacies of ABT263 and ARV825 in vitro, and in mouse models, ketogenic diet adoption or SGLT2 inhibition similarly potentiated ABT263-induced and ARV825-induced senolysis, reducing metastasis and tumor growth. These findings suggest that mitochondrial quality control is a key determinant of resistance to ABT263-induced and ARV825-induced senolysis, providing a possible framework for rational combination senotherapies.

Cellular senescence is a stable form of cell-cycle arrest triggered by a variety of potentially oncogenic stresses, such as telomere erosion, oxidative stress, radiation or oncogene activation[1,2]. While this response prevents the expansion of cells at risk of malignant transformation and thereby acts as a tumor-suppressive mechanism, senescent cells also have a darker side[3]. They secrete pro-inflammatory factors collectively known as the senescence-associated secretory phenotype (SASP)[4–6], which can promote tissue dysfunction and disease depending on the biological context[7–9]. Accordingly, the targeted elimination of senescent cells by 'senolytic' drugs has emerged as a promising therapeutic strategy[10,11]. Over the past decade, more than 20 candidate senolytic drugs have been reported, spanning diverse mechanisms of action[12]. However, despite this growing list, there has been no systematic head-to-head comparison of their efficacies and specificities[10–12]. As a result, it remains unclear which agents most effectively eliminate senescent cells while sparing non-senescent counterparts[12]. Furthermore,

[1]Research Institute for Microbial Diseases (RIMD), The University of Osaka, Suita, Japan. [2]Shiga University of Medical Science, Otsu, Japan. [3]Graduate School of Medicine, Kyoto University, Kyoto, Japan. [4]Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. [5]Graduate School of Science, The University of Osaka, Toyonaka, Japan. [6]Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan. [7]Immunology Frontier Research Center, The University of Osaka, Suita, Japan. [8]Center for Infectious Diseases Education and Research, The University of Osaka, Suita, Japan. e-mail: ehara@biken.osaka-u.ac.jp

even the most potent senolytic drugs fail to eliminate a subset of resistant cells, but the mechanisms underlying this resistance remain poorly understood[10–12]. In this study, we systematically compared 21 senolytic agents using a quantitative senolytic specificity index (SSI), identified ABT263 (ref. 13) and ARV825 (ref. 14) as the most effective senolytics across fibroblast and epithelial models, and uncovered mitochondrial quality control as a key determinant of resistance to senolysis.

Results

Systematic comparison of reported senolytic drugs

We conducted a comparative analysis of the activities and specificities of 21 reported senolytic drugs (ABT199, ABT263, ABT737, ARV825, BPTES, CB839, dasatinib and quercetin (D + Q), digoxin, fisetin, gingerenone A, IMP1088, JQ1, nintedanib, OTX015, PCC1, PCLX-001, P5091, RG7112, R406, 17-DMAG and 25-hydroxycholesterol)[13–25] in targeting and eliminating senescent cells (Fig. 1a). To this end, we utilized IMR-90, a representative line of normal human diploid fibroblasts (HDFs) that has historically served as a prototypical model in cellular senescence research[26], and the epithelial cell line RPE-1, widely used for studying epithelial cell senescence[27], which were both induced into senescence (replicative and doxorubicin (DXR) induced, respectively; Fig. 1a). The senescent state was confirmed by several markers[28], including increases in $p16^{INK4a}$ and $p21^{WAF1/CIP1}$, reduction in lamin B1 and loss of EdU incorporation, in both replicative and DXR-induced models (Supplementary Fig. 1). Senescent and non-senescent cells were treated with varying concentrations of these compounds, including the optimal doses reported previously[13–25]. To quantify specificity, we introduced an SSI, defined as SSI = (percentage senescent cells eliminated on day 3 relative to day 0)/(percentage reduction in control cell number on day 2 relative to untreated control cells).

Because control cells typically reach confluence by day 3, their cell number could not be reliably assessed at this time point; therefore, we used their cell counts on day 2. A higher SSI indicates greater specificity toward senescent cells, reflecting efficient elimination relative to adverse effects on controls. Using this metric, we confirmed that most compounds displayed senolytic activity, albeit to varying degrees (Fig. 1b,c and Extended Data Figs. 1 and 2). However, at concentrations that did not affect the proliferation and survival of non-senescent (control) cells in both IMR-90 and RPE-1 cells, only the Bcl-2 family inhibitors ABT263 (ref. 13) and ABT737 (ref. 19) and the BET inhibitor ARV825 (ref. 14) demonstrated high efficacy (Fig. 1b,c and Extended Data Figs. 1 and 2). Moreover, although the results may vary depending on cell type and senescence-inducing method, ABT263 and ARV825 consistently achieved the highest SSI values in both IMR-90 and RPE-1 cells (Fig. 1b,c and Extended Data Figs. 1 and 2). Similar results were obtained with senescence induced by other methods, as well as in other fibroblast lines (Fig. 1d–f). Notably, using control cells treated with the concentration of each compound yielding the maximal SSI, Annexin V staining, which detects phosphatidylserine exposure (a hallmark of early apoptosis), revealed apoptotic responses in a subset of cells for most compounds, except ABT199 (ref. 19), ABT263 (ref. 13), ABT737 (ref. 19), ARV825 (ref. 14), digoxin[17,18] and OTX015 (ref. 14), particularly in IMR-90 cells (Extended Data Fig. 3). These results further support ABT263 and ARV825 as the most promising senolytic candidates in the models examined here, although senolytic sensitivity can vary depending on cell type and biological contexts. Indeed, preadipocytes have been reported to be relatively resistant to BCL-XL inhibition, including that by ABT263 (ref. 29). Importantly, even with these potent agents, complete elimination of senescent cells was not achievable, as approximately 20% to 30% of the senescent cells survived even at prolonged time points (Fig. 1g).

V-ATPase-dependent mitochondrial quality control promotes resistance to ABT263 and ARV825

To investigate why a subset of senescent cells remained resistant, we next examined the characteristics of the surviving population. RNA-sequencing (RNA-seq) analysis revealed 51 upregulated genes and 71 downregulated genes in common, in senescent fibroblasts that survived ABT263 or ARV825 treatment (Extended Data Fig. 4a). Differentially expressed genes (DEGs) and Gene Ontology (GO) analyses showed that many upregulated genes encoded SASP factors (Extended Data Fig. 4b). This was confirmed by quantitative PCR with reverse transcription (RT–qPCR) and immunofluorescence analysis (Extended Data Fig. 4c,d). The persistence of senescent cells with heightened SASP expression may diminish therapeutic benefit, underscoring the need to clarify resistance mechanisms and develop strategies to overcome them. Reanalysis of gene expression suggests increased oxidoreductase activity, including elevated expression of *AKR1C1–AKR1C3*, which are involved in detoxification of reactive carbonyl species and reduction of oxidative stress (Extended Data Fig. 4b,e). Although some of these genes might simply become upregulated by the reduction of BRD4 (ref. 30) in ARV825-treated cells, this expression pattern is suggestive of preserved mitochondrial membrane potential and reduced reactive oxygen species (ROS) accumulation (Extended Data Fig. 4b,e). Notably, ABT263, a BH3 mimetic, inhibits anti-apoptotic Bcl-2 family proteins, thereby enabling activation of BAX/BAK and subsequent mitochondrial outer membrane permeabilization and cytochrome c release[13]. We therefore hypothesized that ABT263-resistant cells maintain mitochondrial function. Indeed, MT-1 staining, an indicator of mitochondrial membrane potential[31], showed that most senescent cells displayed reduced mitochondrial membrane potential 2–3 days after ABT263 treatment, but many of the resistant cells that persisted after 7 days retained strong MT-1 signals (Extended Data Fig. 5a). Conversely, ROS levels, which typically increase with mitochondrial dysfunction and contribute to cellular damage[32], rose on days 2–3 but declined by day 7 in surviving cells (Extended Data Fig. 5b). Furthermore, treatment with the antioxidant *N*-acetyl-L-cysteine reduced ABT263-induced senolysis (Extended Data Fig. 5c), supporting a role for preserved mitochondrial function in the survival of ABT263-resistant senescent cells.

Because MT-1 could not be combined with apoptosis markers such as Annexin V for double staining, we searched for an alternative indicator of mitochondrial function. To this end, we performed single-cell RNA sequencing (scRNA-seq) to identify candidate genes for this purpose. The scRNA-seq analysis revealed that a series of genes

Fig. 1 | Comparative analysis of senolytic drugs revealed ABT263 and ARV825 as the most potent compounds. a, Outline of the comparative analysis of senolytic drug. Early-passage HDFs (IMR-90 cells) and RPE-1 epithelial cells were rendered senescent by serial passaging (Rep-Sen cells) or treatment with 150 ng ml^{-1} DXR for 10 days (DXR-Sen cells), respectively. Senescent and non-senescent (control) cells were treated with 21 compounds at multiple concentrations for 3 days. Relative cell numbers were determined throughout the experiments. If the reduction of control cells on day 2 was <1%, the denominator was set to 1. Created with BioRender.com. **b**,**c**, For each compound, the SSI value at the concentration yielding the highest index is shown. (See Extended Data Figs. 1 and 2 for actual data). **d**–**f**, Early-passage pre-senescent normal HDFs (IMR-90 (**d**), TIG-3 (**e**), and TIG-1 (**f**)) were rendered senescent by serial passaging (Rep-Sen cells; **e**) or by treatment with 250 ng ml^{-1} DXR for 10 days (DXR-Sen cells; **d**,**e**), or by treatment with 100 μM etoposide for 2 days followed by a 10-day recovery period (ETO-Sen cells; **f**). Control and senescent cells were treated with the indicated compounds for 3 days (**d**–**f**). Relative cell numbers were determined throughout the experiments. **g**, Early-passage (control) TIG-3 cells were rendered senescent by treatment with 250 ng ml^{-1} DXR for 10 days (DXR-Sen cells) or by serial passaging (Rep-Sen cells). These senescent and control cells were then incubated with ABT263 (0.5 μM) or ARV825 (25 nM) for 7 days. Relative cell numbers were determined by daily cell counts. Data are presented as the mean ± s.d. (**d**–**g**). Representative results from three independent experiments are shown. DMSO, dimethylsulfoxide.

https://doi.org/10.1038/s43587-025-01057-z









https://doi.org/10.1038/s43587-025-01057-z



c

	Gene	Avg. log_2 FC	P_{adj}
*	*ATP6VOE1*	1.057	8.615×10^{-222}
	NDUFV3	0.988	5.237×10^{-185}
*	*ATP6V1E1*	0.985	6.963×10^{-142}
	CYCS	0.905	3.381×10^{-82}
*	*ATP5PD*	0.876	4.383×10^{-162}
	UQCRB	0.858	6.983×10^{-165}
	NDUFA3	0.852	5.459×10^{-119}
*	*ATP6V1F*	0.849	4.013×10^{-93}
	COX7A1	0.830	4.689×10^{-32}
*	*ATP5F1E*	0.829	2.330×10^{-139}
	UQCRH	0.812	7.339×10^{-111}
	NDUFA2	0.810	6.079×10^{-104}
	COX4I1	0.782	3.135×10^{-106}
	COX6A1	0.760	2.611×10^{-88}
	NDUFB2	0.754	2.781×10^{-85}

*V-ATPase-coding genes



encoding subunits of the V-ATPase, which is required for the lysosomal clearance of damaged mitochondria[33], such as *ATP6VOE1*, were among the top commonly expressed genes in both ABT263-resistant and ARV825-resistant senescent cells (Fig. 2a–c). Notably, the *ATP6VOE1* knockdown significantly reduced MT-1 signals and cell survival in ABT263-treated senescent cells (Extended Data Fig. 6a–c), whereas treatment with EN6, a V-ATPase activator, produced opposite effects (Extended Data Fig. 6d,e), suggesting an association between *ATP6VOE1* expression and mitochondrial membrane potential. We then performed double staining with MT-1 and *ATP6VOE1* and found that senescent cells displayed substantial heterogeneity in both signals (Fig. 2d). After ABT263 treatment, cells with very low MT-1 fluorescence

Fig. 2 | Heterogeneity of senescent cells underlies resistance to ABT263 and ARV825. a, Uniform manifold approximation and projection (UMAP) embedding of scRNA-seq profiles from early-passage pre-senescent (control) TIG-3 cells and DXR-induced senescent (DXR-Sen) TIG-3 cells treated with or without ABT263 or ARV825 for 7 days. **b**, Top ten enriched biological processes from Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of upregulated DEGs in group A. KEGG pathway enrichment analysis was performed using a one-sided Fisher's exact test, with *P* values adjusted for multiple testing using the Benjamini–Hochberg false discovery rate (FDR) method; pathways with FDR < 0.05 were considered significant. **c**, Genes belonging to the top-ranked KEGG pathway 'OXPHOS'. Differential gene expression analysis was performed using a two-sided MAST hurdle model implemented in Seurat. *P* values were adjusted for multiple testing using the Benjamini–Hochberg FDR method. **d**,**e**, DXR-Sen TIG-3 cells were incubated with ABT263 (0.5 μM) or ARV825 (25 nM) for the indicated durations and subjected to MT-1 staining together with *ATP6V0E1* RNA in situ hybridization (**d**), or Annexin V staining together with *ATP6V0E1* RNA in situ hybridization (**e**). Nuclei were counterstained with DAPI. Representative images at each time point are shown; enlarged views of the regions outlined with yellow dashed lines are shown in the lower-left corners. Scale bars, 10 μm. Signal intensities of individual cells are plotted. Areas with both MT-1 and *ATP6V0E1* fluorescence signals ≤ 15 (**d**), or with Annexin V fluorescence signals ≥5 and *ATP6V0E1* signals ≤ 5 (**e**), are outlined with red dashed lines, and the percentage of cells within each area is indicated in red. The *r* values at the top of each graph indicate the correlation coefficient between the *x*-axis and *y*-axis variables. At least 50 cells were scored per group. Representative data from three independent experiments are shown. AFUs, arbitrary fluorescence units.

(≤15 fluorescence units) increased between days 1 and 5 but decreased by day 7. Up to this time, the surviving cells had shown a remarkable increase in the correlation coefficient between MT-1 signal intensity and *ATP6V0E1* expression (Fig. 2d). Furthermore, double staining for *ATP6V0E1* and Annexin V demonstrated that cells with very low *ATP6V0E1* expression (≤5 fluorescence units) became Annexin V-positive from days 1 to 3 after ABT263 treatment but were no longer detectable on day 7 (Fig. 2e). It is also important to note that the depletion of mitochondria[34,35] significantly attenuated the senolytic activity of ABT263, indicating that the accumulation of damaged mitochondria is a critical determinant of senolysis in this experimental setting (Extended Data Fig. 7). Importantly, comparable results were also obtained with ARV825 (Fig. 2 and Extended Data Figs. 5–7). Taken together, these results suggest that senescent cells are heterogeneous with respect to V-ATPase expression. Cells with low V-ATPase expression may fail to clear damaged mitochondria upon treatment with ABT263 or ARV825, leading to ROS accumulation and cell death, whereas cells with high V-ATPase expression are likely to remove damaged mitochondria more efficiently, preventing ROS accumulation and thereby surviving (Fig. 2 and Extended Data Figs. 5–7).

Glycolysis-to-OXPHOS shift raises mitochondrial load, boosting senolysis by ABT263 and ARV825

Because BRD4, a major target of ARV825, has been implicated in regulating mitochondrial gene expression[36], we examined this possibility but did not observe a notable effect in senescent HDFs (Supplementary Fig. 2). Instead, ARV825 is known to downregulate XRCC4 (ref. 14), which functions with DNA ligase IV in nonhomologous end joining[14,37], via the reduction in BRD4 (Extended Data Fig. 8a–c). Interestingly, XRCC4 has also been reported to localize to mitochondria, where it associates with DNA ligase III[38], which shares structural similarity with DNA ligase IV. In line with this, we found that XRCC4 binds to DNA ligase III and colocalizes with mitochondria in senescent cells (Extended Data Fig. 8d,e). Consistent with this, both XRCC4 and DNA ligase III knockdowns closely phenocopied the effects of ARV825 and ABT263 treatments (Extended Data Fig. 8f–k). Collectively, these findings indicate that ARV825 promotes senescent cell death, at least in part, by compromising mitochondrial function, suggesting that mitochondrial quality control is likely a key determinant of resistance to ABT263-induced and ARV825-induced senolysis. To further confirm this idea, we applied mitochondrial stress by short interfering RNA (siRNA)-mediated depletion of DNA polymerase subunit gamma (PolG), the only polymerase responsible for mitochondrial DNA (mtDNA) replication[39,40], in DXR-induced senescent cells. Notably, PolG depletion alone caused a slight but statistically significant decrease in mitochondrial membrane potential (Extended Data Fig. 9a–d). However, combining PolG depletion with ABT263 or ARV825 further reduced mitochondrial membrane potential and increased ROS levels (Extended Data Fig. 9a–e), resulting in a marked increase in senescent cell death (Extended Data Fig. 9f). Importantly, these effects were not observed in non-senescent control cells (Extended Data Fig. 9). Together, these results suggest that imposing mitochondrial stress aggravates the decline in mitochondrial function induced by ABT263 and ARV825, thereby enhancing senolysis.

We therefore sought a more physiological means to impose mitochondrial stress and focused on the metabolic shift from glycolysis to oxidative phosphorylation (OXPHOS) induced by a low-carbohydrate diet[41,42]. To mimic this effect in cultured cells, we initially used low-glucose medium. However, this approach also reduced the expansion of actively proliferating cells[43], raising concerns about nonspecific effects. Accordingly, we tested an alternative strategy: inhibition of GLUT1 signaling. BAY876 (ref. 44), a highly specific GLUT1 inhibitor, suppresses glycolysis and thereby forces a compensatory shift toward mitochondrial dependence, resulting in increased TCA cycle activity, elevated oxygen consumption rate (OCR) and increased reliance on OXPHOS. Treatment of DXR-induced senescent TIG-3 fibroblasts with BAY876 in normal medium induced this metabolic shift from glycolysis to OXPHOS (Fig. 3a). Moreover, a significant decrease in mitochondrial membrane potential and an increase in ROS levels were observed when ABT263 or ARV825 was combined with BAY876 treatment in senescent cells, but not in control cells (Fig. 3b,c). Furthermore, the efficiency of senescent cell death induced by ABT263 or ARV825 was substantially enhanced by cotreatment with BAY876 (Fig. 3d). Similar results were also observed when cellular senescence was induced in different cell types (Supplementary Fig. 3). These results, in conjunction with the observation that glycolysis is accelerated in senescent cells and that redox homeostasis is maintained[45], lead us to propose that a metabolic shift from glycolysis to OXPHOS increases mitochondrial workload and stress, thereby substantially enhancing the senolytic effects of ABT263 and ARV825.

Fig. 3 | Metabolic shift from glycolysis to OXPHOS by BAY876 enhances the senolytic activity of ABT263 and ARV825. a, Early-passage pre-senescent (control) or DXR-Sen TIG-3 cells were incubated with or without 7 μM BAY876 for 3 days and then subjected to Seahorse analysis to measure OCR following sequential injection of oligomycin (O, 1.5 μM), FCCP (F, 1 μM) and rotenone plus antimycin A (R/A, 0.5 μM). Basal respiration, maximal respiration and ATP production rates are shown to the right. **b**–**d**, Control TIG-3 cells and DXR-Sen TIG-3 cells were treated with the indicated compounds and subjected to MT-1 staining to assess mitochondrial membrane potential (**b**), CellROX staining to measure intracellular ROS levels (**c**) or cell number quantification (**d**). MT-1 and CellROX analyses were performed 2 days after treatment; 58 cells (**b**), 60 cells in control cells and 51 cells in DXR-Sen cells (**c**) were scored per group. Data are presented as the mean ± s.d. (**a**–**d**). Statistical significance was determined by two-sided Student's *t*-test (**a**), one-way analysis of variance (ANOVA) followed by Sidak's test (**b** and **c**) or two-sided Welch's *t*-test (**d**). Scale bars, 10 μm (**b** and **c**). Although data shown are from technical replicates (**a**–**d**), experiments were independently repeated at least once to confirm reproducibility.

https://doi.org/10.1038/s43587-025-01057-z

Carbohydrate restriction enhances the in vivo efficacy of mitochondria-targeting senolytic therapies

To determine whether metabolic imposition of mitochondrial stress enhances the senolytic efficacy of ABT263 and ARV825 in vivo, we next tested this concept in mouse models using male mice. Senescent cells are known to promote cancer growth and metastasis through secretion of SASP factors, depending on the biological context[3]. In particular, B16 melanoma cells transplanted via the tail vein reportedly accumulate preferentially in the lungs of older mice, where senescent cells are more abundant, than in younger mice[46]. Therefore, we investigated whether



https://doi.org/10.1038/s43587-025-01057-z



administering a low-carbohydrate ketogenic diet[47,48] together with ABT263 or ARV825 treatment in aged mice would further reduce the number of senescent cells in the lungs and decrease the accumulation of B16 melanoma cells. To exclude the possibility that the ketogenic diet and/or senolytic drugs directly affect the B16 melanoma cells, both interventions were discontinued 3 weeks before the transplantation of B16 melanoma cells (Fig. 4a,b). In aged mice fed a normal diet, the numbers of $p16^{INK4a}$-positive and $p21^{WAF1/CIP1}$-positive but Ki67-negative cells decreased in both the ABT263-treated and ARV825-treated lungs (Fig. 4c and Extended Data Fig. 10a,b). Moreover, there was a trend toward reduced accumulation of B16 cells in the lungs compared with vehicle-treated mice (Fig. 4d), and these effects were more pronounced in mice fed a ketogenic diet (Fig. 4c,d and Extended Data Fig. 10a,b). Notably, the expression of *Cxcl2* and *Cxcl12*, genes encoding SASP factors known to promote B16 cell migration[49,50], was substantially reduced in mice receiving both a ketogenic diet and senolytic drug

Fig. 4 | Metabolic intervention enhances the inhibitory effects of senolytic drugs on tumor growth and metastasis in mice. a, Experimental timeline ($n = 9$–10 per group). Red arrows indicate administration of ABT263, ARV825 or vehicle for 5 consecutive days each week for 2 weeks. Black arrows denote daily feeding with a normal diet (ND) or ketogenic diet (KD); blue arrows indicate daily feeding with ND only. **b**, Blood glucose concentrations measured at week 94. **c**–**e**, Mice were euthanized at week 100, and tumor-free areas of the lungs were dissected and subjected to the following analyses: **c**, Expression levels of *p16*^{INK4a} and *p21*$^{WAF1/CIP1}$ by RT–qPCR. **d**, Representative macroscopic lung images and quantification of metastatic nodules. **e**, Expression levels of *Cxcl2* and *Cxcl12* by RT–qPCR. **f**, Experimental timeline. On day −7, nude mice received subcutaneous transplantation of HCT116 cells. The blue arrow indicates daily treatment with DXR for 7 consecutive days. Red arrows denote administration of ABT263, ARV825 or vehicle for 5 consecutive days each week for 2 weeks. The black arrow indicates continuous access to dapagliflozin (SGLT2 inhibitor) or vehicle. **g**, Blood glucose concentrations on day 18. **h**, Tumor volumes measured every other day with calipers in biologically independent animals: control + vehicle ($n = 9$), control + ABT263 ($n = 9$), control + ARV825 ($n = 9$), SGLT2i + vehicle ($n = 8$), SGLT2i + ABT263 ($n = 9$) and SGLT2i + ARV825 ($n = 8$). **i**,**j**, Mice were euthanized, and serial sections of xenograft tumors were analyzed by immunofluorescence for senescence markers (p21$^{WAF1/CIP1}$-positive or 53BP1-positive but Ki67-negative cells). Nuclei were counterstained with DAPI. Enlarged views of regions outlined with yellow dashed lines are shown in the lower-left corners; histograms to the right show the percentages of positive cells, quantified from four fields per mouse across five mice per group. Although data shown are from technical replicates (**b**–**e** and **g**–**j**), experiments were independently repeated at least once to confirm reproducibility. Data are presented as the mean ± s.d. (**b**–**e** and **g**–**j**). Statistical significance was assessed by a two-sided Student's or Welch's *t*-test (**b**–**e** and **g**–**j**). Scale bars, 10 mm (**d**) and 10 μm (**i** and **j**).

treatment (Fig. 4e). Although a recent report showed that ketogenic diets can induce cellular senescence in several mouse tissues[51], we did not observe such an effect at least in the lungs of aged mice. This suggests that the impact of a ketogenic diet on cellular senescence may be age dependent. Taken together, these findings indicate that combining a ketogenic diet with mitochondria-targeting senolytic drugs such as ABT263 or ARV825 can effectively reduce the burden of senescent cells, at least in the lungs of aged mice, thereby attenuating cancer cell accumulation.

To further explore the enhanced effects of combining a ketogenic diet with ABT263 or ARV825 in an animal model of cancer therapy, we used a therapy-induced senescence model[28], as surviving cancer cells after chemotherapy can drive recurrence and progression. Our previous report showed that the concurrent administration of DXR, an anticancer drug known to induce cellular senescence, with ARV825 modestly improved the antitumor efficacy of DXR in a xenograft model using HCT116 colorectal cancer cells[14]. Moreover, at the concentrations used in our senolysis assays, neither ARV825 nor ABT263 alone inhibited the proliferation of HCT116 cells. A reduction in cell numbers was observed only when cells had been pretreated with DXR, consistent with senolysis-dependent cell death (Supplementary Fig. 4). We therefore investigated whether a ketogenic diet could further augment the efficacy of DXR combined with ARV825 or ABT263 in the same xenograft mouse model. However, when nude mice bearing HCT116 xenografts were treated with DXR while fed a ketogenic diet, many died. This outcome may reflect the known risk of severe side effects, such as ketoacidosis, in individuals on an extremely low-carbohydrate diet, especially under stress or in type 2 diabetes[52]. To overcome this limitation, we tested the sodium–glucose cotransporter 2 (SGLT2) inhibitor, which reduces blood glucose by blocking renal reabsorption, as an alternative means to lower glucose availability[53]. This approach decreased blood glucose levels without causing lethality in the xenograft model (Fig. 4f,g). Notably, the administration of DXR followed by a combined treatment with an SGLT2 inhibitor and ARV825 or ABT263 resulted in significantly stronger inhibition of tumor growth compared to individual treatments (Fig. 4h). In parallel, tumors exhibited a significant reduction in p21$^{WAF1/CIP1}$-positive and 53BP1-positive but Ki67-negative cells, markers of senescence, together with increased ROS and apoptosis markers (Fig. 4i,j and Extended Data Fig. 10c,d). Collectively, these results suggest that ARV825 and ABT263 may exhibit further enhanced senolytic activity and improved suppression of tumor growth and metastasis when combined with a carbohydrate signaling blockade (see the model in Supplementary Fig. 5). Nevertheless, we cannot fully exclude the possibility that the observed antitumor effects may partially involve senolysis-independent actions of ABT263 and ARV825.

Discussion

Our study systematically compared reported senolytic drugs by the SSI and identified ABT263 and ARV825 as the most effective agents in our models (Fig. 1b,c and Extended Data Figs. 1 and 2). Both targeted mitochondrial function, yet a subset of senescent cells survived by maintaining mitochondrial integrity, at least in part, through V-ATPase-mediated clearance of damaged mitochondria (Fig. 2 and Extended Data Fig. 6). These findings indicate that senescent cell heterogeneity[54–56], increasingly recognized in the field, is a key determinant of senolysis resistance. Thus, the mechanisms underlying senolytic efficacy and resistance may vary depending on cell type and context. Nevertheless, we demonstrate that metabolic interventions already in clinical use, such as ketogenic diets[47,48] or SGLT2 inhibitors[53], can increase mitochondrial workload and thereby induce mitochondrial stress, enhancing the senolytic efficacy of ABT263 and ARV825 in vivo (Fig. 4 and Extended Data Fig. 10). While our findings provide proof of principle that senolytic efficacy can be modulated in vivo, the effects of metabolic modulation are likely context dependent[51,52], with potential consequences for SASP[3,10–12], immune surveillance of senescent cells[57] and tissue homeostasis[9,58]. Approaches using antibodies[59–62] or chimeric antigen receptor T cells[63] also underscore the potential of senolysis, although compound-based strategies may be advantageous for reversible modulation. Notably, a recent study by Fielder et al. reported that mitochondrial stress can potentiate the senolytic activity of ABT263 (ref. 64). In that report, mitochondrial uncoupling or galactose culture increased mitochondrial workload and sensitized senescent cells to ABT263 (ref. 64). This is consistent with our conclusion that mitochondrial quality control is a central determinant of senolytic resistance to mitochondria-targeting senolytic drugs, and our findings extend this concept by suggesting the potential for translational dietary and pharmacological interventions that are already clinically available. One limitation of this study is that all in vivo experiments were performed using male mice; therefore, the generalizability of our findings to female mice remains to be determined. Collectively, these observations suggest possible avenues for developing rational combination senotherapies.

Methods

Ethical approval

All animal experiments were approved by the Animal Research Committee of the Research Institute for Microbial Diseases, The University of Osaka.

Chemicals

The following chemicals were used: ABT263 (S1001, Selleck Chemicals), ABT737 (S1002, Selleck Chemicals), ABT199 (16233, Cayman Chemical), ARV825 (HY-16954, MedChemExpress), JQ1 (HY-13030, MedChemExpress), OTX015 (S7360, Selleck Chemicals), 17-DMAG (S1142, Selleck Chemicals), BPTES (19284, Cayman Chemical), CB839 (S7655, Selleck Chemicals), P5091 (S7132, Selleck Chemicals), RG7112 (S7030, Selleck Chemicals), IMP1088 (HY-112258, MedChemExpress), PCLX-001 (E1217, Selleck Chemicals), nintedanib (S1010, Selleck Chemicals), R406 (S2194, Selleck Chemicals), 25-hydroxycholesterol (HY-113134,

MedChemExpress), digoxin (S4290, Selleck Chemicals), procyanidin C1 (HY-N2342, MedChemExpress), gingerenone A (HY-120912, MedChemExpress), fisetin (S2298, Selleck Chemicals), dasatinib (S1021, Selleck Chemicals), quercetin (10005169, Cayman Chemical), DXR (046-21523, FUJIFILM Wako Chemicals), etoposide (341205, Sigma-Aldrich), DAPI (340-07971, Dojindo), Hoechst 33342 (H342, Dojindo), *N*-acetyl-L-cysteine (013-05133, FUJIFILM Wako Chemicals), BAY876 (S8452, Selleck Chemicals), dapagliflozin (S1548, Selleck Chemicals) and EN6 (S6650, Selleck Chemicals).

Cell culture

IMR-90, TIG-1 and TIG-3 human fibroblasts, as well as B16BL6 mouse melanoma cells, were obtained from public bioresource banks. RPE-1 and HCT116 cells were obtained from Lonza and the American Type Culture Collection, respectively. IMR-90, TIG-3, RPE-1, HCT116 and B16BL6 cells were maintained in Dulbecco's Modified Eagle's medium supplemented with 10% fetal bovine serum and 100 U ml^{-1} penicillin–streptomycin. TIG-1 cells were cultured in Modified Eagle's medium supplemented with 10% fetal bovine serum and 100 U ml^{-1} penicillin–streptomycin. All cell lines were routinely tested and confirmed to be negative for mycoplasma contamination. None of the cell lines used in this study are listed as misidentified or cross-contaminated by the International Cell Line Authentication Committee. Cell line authentication was not performed by the authors but was guaranteed by the supplier. For in vitro studies, cells were seeded and randomly allocated to experimental groups.

Mice

C57BL/6J and nude (nu/nu) mice were obtained from a commercial vendor (CLEA Japan). Mice were housed under specific pathogen-free conditions at 23 °C ± 2 °C and 55% ± 15% humidity on a 12-h light–dark cycle, with ad libitum access to either a normal diet (CE-2, CLEA Japan; 12 kcal% fat, 29 kcal% protein, 59 kcal% carbohydrates) or a ketogenic diet (D10070801, Research Diets; 90 kcal% fat, 10 kcal% protein, 0 kcal% carbohydrates). Experiments were performed in parallel under identical conditions. The maximal permitted tumor burden approved by the institutional Animal Research Committee was a tumor volume of ≤1,500 mm^3 or a maximum diameter of ≤15 mm. Tumor size was monitored regularly, and animals were euthanized at the end of the experiments. The maximal permitted tumor size/burden was not exceeded in any experiment.

Lung metastasis assay

Before tumor inoculation, 87-week-old male C57BL/6J mice (n = 9 to 10 per group) were fed a normal diet or a ketogenic diet for 5 weeks. Mice then received oral administration of ABT263 (100 mg per kg body weight) or vehicle, dissolved in a mixture of 10% ethanol, 30% polyethylene glycol 400 and 60% Phosal 50 PG[65], or intraperitoneal administration of ARV825 (5 mg per kg body weight) or vehicle, dissolved in 10% DMSO, 40% PEG300, 5% Tween-80 and 45% saline[14], for 5 consecutive days per week over 2 weeks. After this treatment, ketogenic diet-fed mice were switched to a normal diet for 3 weeks. Subsequently, mice were injected with 1×10^5 B16BL6 cells into the tail vein. Three weeks later, lungs were collected, surface metastatic nodules were counted, and the tissues were subjected to RT–qPCR and immunofluorescence analyses.

Xenograft tumor assay

HCT116 cells (5×10^5) were mixed at a 1:1 (vol/vol) ratio with Matrigel (BD Biosciences) and injected subcutaneously into 6–8-week-old male nude mice (n = 8 to 9 per group). After intraperitoneal administration of DXR (1 mg per kg body weight) for 7 consecutive days, mice received dapagliflozin (SGLT2 inhibitor; 0.0125 mg ml^{-1} in drinking water, approximate daily dose of 2.5 mg per kg body weight) together with ABT263 (100 mg per kg body weight)[65], ARV825 (5 mg per kg body weight)[14] or vehicle, for 5 consecutive days per week over 2 weeks. Tumor size was measured using a Vernier caliper, and tumor volume (mm^3) was calculated as (length × $width^2$)/2. Tumor tissues were subjected to immunofluorescence analyses.

Blood glucose measurement

Blood glucose levels were measured using a Freestyle Glucose Monitoring System (71386-80, 80224-75; Abbott Laboratories).

Induction of senescence in vitro

For DXR-induced senescence, IMR-90, TIG-3, RPE-1 and HCT116 cells were incubated with DXR at 250 ng per ml, 250 ng per ml, 100 ng per ml and 200 ng per ml, respectively, for 10 days. For etoposide-induced senescence, TIG-1 cells were incubated with etoposide at 100 μM for 2 days. For replicative senescence, IMR-90 and TIG-3 cells were serially passaged until they exceeded 73 population doublings.

Cell proliferation and survival assay

Cells were seeded in 12-well plates, and cell numbers were counted daily at identical grid positions using gridded culture dishes. Relative cell numbers were calculated by normalizing to the initial count on day 0, which was set as 100%.

RNAi

RNA interference (RNAi) was performed by transfecting previously validated siRNA oligonucleotides using Lipofectamine RNAiMAX (13778150; Thermo Fisher Scientific) according to the manufacturer's instructions. The siRNAs used were as follows: LIG3 (1: Dharmacon, ON-TARGETplus siRNA, ID: L-009227-00-0005; 2: Thermo Fisher Scientific, Silencer Select Pre-Designed siRNA, ID: s8177); POLG (1: Dharmacon, ON-TARGETplus siRNA, ID: L-012649-00-0005; 2: Thermo Fisher Scientific, Silencer Select Pre-Designed siRNA, ID: s10789); XRCC4 (1: Dharmacon, ON-TARGETplus siRNA, ID: L-004494-00-0005; 2: Thermo Fisher Scientific, Silencer Select Pre-Designed siRNA, ID: s14951); ATP6V0E1 (Dharmacon, ON-TARGETplus siRNA, ID: L-011559-01-0005); BRD4 (Dharmacon, siGENOME siRNA, ID: M-004937-02-0005); and control (Dharmacon, ON-TARGETplus Non-targeting siRNA, ID: D-001810-0X).

Western blotting

Cell pellets were lysed in RIPA buffer containing protease inhibitor cocktail (25955-11; Nacalai Tesque). Protein concentrations were determined using a Protein Assay kit (740967.250; Takara Bio). Samples were denatured in Laemmli sample buffer for 5 min at 95 °C, separated by SDS–PAGE, and transferred onto polyvinylidene difluoride membranes (EMD Millipore). After blocking with 5% milk, membranes were incubated with primary antibodies: β-actin (1:2,000 dilution; A5316, Sigma-Aldrich), lamin B1 (1:1,000 dilution; ab16048, Abcam), p16 (1:1,000 dilution; sc-56330, Santa Cruz), p21 (1:1,000 dilution; 2947, Cell Signaling Technology), XRCC4 (1:1,000 dilution; sc-271087, Santa Cruz), LIG3 (1:1,000 dilution; sc-135883, Santa Cruz), POLG (1:1,000 dilution; ab128899, Abcam), ATP6V0E1 (1:1,000 dilution; PA5-1114887, Thermo Fisher Scientific) and BRD4 (1:1,000 dilution; 13440, Cell Signaling Technology). Membranes were then incubated with horseradish peroxidase-conjugated secondary antibodies (1:2,000 dilution; 7074 and 7076, Cell Signaling Technology) and visualized using Amersham ECL Prime/Select (GE Healthcare), followed by detection with ImageQuant 800 (Cytiva).

Immunoprecipitation

Immunoprecipitation was performed using Dynabeads Protein G (10004D, Thermo Fisher Scientific). Protein lysates were pre-cleared by incubation with Dynabeads Protein G at 4 °C for 30 min in immunoprecipitation buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail). The pre-cleared lysates

were then incubated overnight at 4 °C with 3 µg of antibody against XRCC4 (sc-271087, Santa Cruz Biotechnology), LIG3 (sc-135883, Santa Cruz Biotechnology) or control IgG (5415, Cell Signaling Technology). Immune complexes were captured with 30 µl Dynabeads Protein G at room temperature for 2 h, washed and analyzed by immunoblotting as described above.

Immunohistochemistry

Dissected tissues were fixed in Bouin's solution for 2 h (for p16 staining)[66] or in 4% paraformaldehyde (PFA) overnight at 4 °C (for all other staining), then embedded in paraffin and sectioned at 5 µm. Sections were deparaffinized and subjected to heat-mediated antigen retrieval in citrate buffer (pH 6.0). After permeabilization with 0.1% Triton X-100, sections were blocked with BLOXALL (SP-6000, Vector) and 2.5% normal horse serum, followed by incubation with primary antibodies.

Primary antibodies used were p16 (1:1000; ab211542, Abcam) for Bouin's-fixed mouse samples[66], and p21 (1:1,000 dilution, 2947, Cell Signaling; 1:1,000 dilution, ab188224, Abcam), Ki67 (1:1,000 dilution; 14-5698-82, Thermo Fisher Scientific) and 53BP1 (1:1,000 dilution; NB100-304, Novus Biologicals) for 4% PFA-fixed samples. Sections were incubated with secondary antibodies (ImmPRESS Polymer Anti-Rabbit IgG, Vector, MP-7401) for 30 min. Signal amplification was performed with the TSA TMR System (AKOYA Biosciences, NEL702001KT) following the manufacturer's instructions. Sections were then incubated with secondary antibodies (Alexa Fluor 488, 1:2,000 dilution; A-21208, Thermo Fisher Scientific) and DAPI for 1 h, and mounted with Fluoromount-G (SouthernBiotech, 0100-01). Fluorescence images were acquired with an All-in-One Fluorescence Microscope (BZ-710; Keyence), and the number or area of positive cells was quantified automatically using ImageJ (version 1.54) software.

TUNEL analysis

TUNEL staining was performed on 4% PFA-fixed mouse tissues using the One-step TUNEL In Situ Apoptosis Kit (Red, Elab Fluor 555, E-CK-A325; Elabscience) according to the manufacturer's instructions. Nuclei were counterstained with DAPI (4′,6-diamidino-2-phenylindole). Fluorescence images were acquired with an All-in-One Fluorescence Microscope (BZ-710; Keyence), and the number or area of TUNEL-positive cells was quantified automatically using ImageJ (version 1.54).

Dihydroethidium analysis

Frozen tumors embedded in Tissue-Tek optimal cutting temperature compound (4583, Sakura Finetek) were sectioned at 10 µm using a cryostat at −20 °C. To assess tissue ROS levels, sections were incubated with 5 µM dihydroethidium (HY-D0079, MedChemExpress) for 30 min at 37 °C. After washing with PBS, nuclei were counterstained with DAPI. Fluorescence images were acquired with an All-in-One Fluorescence Microscope (BZ-710, Keyence), and the area or number of dihydroethidium-positive cells was quantified automatically using ImageJ (version 1.54) software.

Cytochemistry

For fluorescence probe staining, cultured cells were incubated with MT-1 (1:1,000 dilution; MT13, Dojindo), 2.5 µM CellROX Deep Red (C10422, Thermo Fisher Scientific) or MitoTracker Red CMXRos (1:1,000 dilution; M7512, Thermo Fisher Scientific) for 30 min and then washed with PBS. After staining with MT-1, cells were fixed with 4% PFA. The MT-1 signal was stable after fixation. Fixed cells were either imaged directly using a TRITC filter or subjected to in situ hybridization for *ATP6V0E1* mRNA based on the hybridization chain reaction (HCR) method. Imaging was performed using identical exposure times and gain settings across all experiments. Fluorescence intensity was measured with ImageJ (version 1.54) after background subtraction. For immunofluorescence staining, cultured cells were fixed with 4% PFA, permeabilized with 0.1% Triton X-100 for 10 min and blocked with 5% horse serum before incubation with primary antibodies (XRCC4, 1:200 dilution, sc-271087, Santa Cruz; CXCL2, 1:50 dilution, AF-452-NA, R&D Systems; GROα/β/γ, 1:50 dilution, sc-365870, Santa Cruz; CXCL5, 1:50 dilution, AF254, R&D Systems; CCL20, 1:50 dilution, AF360, R&D Systems; MMP3, 1:50 dilution, 66338-1-Ig, Proteintech) overnight at 4 °C. The secondary antibody conjugated with Alexa Fluor 488 or Alexa Fluor 555 was applied for 1 h at room temperature. Nuclei were counterstained with DAPI. Fluorescence images were acquired using an All-in-One Fluorescence Microscope (BZ-710; Keyence), and the area or number of positive cells was quantified automatically using ImageJ (version 1.54).

EdU incorporation assay

EdU incorporation was assessed using the Alexa 555 Click-It EdU kit (C10338, Thermo Fisher Scientific) with modifications to the manufacturer's protocol. Cells were incubated with 50 µM EdU for 7 days before fixation. After fixation, two sequential 1-h click reactions were performed with freshly prepared solutions. Coverslips were washed three times with 3% BSA in PBS, and nuclei were counterstained with Hoechst 33342. Fluorescence images were acquired with an All-in-One Fluorescence Microscope (BZ-710, Keyence), and the number or area of positive cells was quantified automatically using ImageJ (version 1.54).

Annexin V immunofluorescence staining

Cultured cells were washed with Annexin-binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM $CaCl_2$, pH 7.4), then incubated with Annexin V Conjugate (A13201, Thermo Fisher Scientific) for 15 min. After incubation, the cells were washed with Annexin-binding buffer and then fixed. Fixed cells were either imaged directly or subjected to in situ hybridization for *ATPV0E1* mRNA based on the HCR method. Nuclei were counterstained with DAPI as described above. Fluorescence images were acquired with an All-in-One Fluorescence Microscope (BZ-710; Keyence), and the number or area of positive cells was quantified automatically using ImageJ (version 1.54).

HCR-based in situ hybridization

Cultured cells were fixed overnight at 4 °C in 4% PFA. After fixation, the cells were treated with methanol for 10 min at room temperature. Hybridization and amplification were performed using the ISHpalette Short Hairpin Amplifier A161-Cyan5 (IPL-B-A161, Nepa Gene) according to the manufacturer's instructions. Nuclei were counterstained with DAPI as described above. Fluorescence images were acquired with an All-in-One Fluorescence Microscope (BZ-710, Keyence), and the number or area of positive cells was quantified automatically using ImageJ (version 1.54).

Oligonucleotide probe sequences used for detecting *ATP6V0E1* mRNA are shown in Supplementary Table 1.

Real-time qPCR analysis

Total RNA was extracted using TRIzol (15596018, Thermo Fisher Scientific) or the RNeasy Mini Kit (74106, Qiagen) according to the manufacturer's instructions. cDNA was synthesized with a commercially available RT Reagent Kit with gDNA Eraser (RR047A; vendor blinded for review). Real-time qPCR was performed on a StepOnePlus PCR System (Applied Biosystems) using TB Green Premix Ex Taq II (RR820A; vendor blinded for review). Expression levels of target genes were normalized to β-actin using the standard ΔΔCt method and expressed relative to the average value of the control cells, which was set to 1. β-actin was used as the internal reference gene following standard qPCR practice. The PCR primer sequences used are shown in Supplementary Table 2.

mtDNA copy number analysis

DNA was extracted from TIG-3 cells using the DNeasy Blood & Tissue Kit (69506, Qiagen). qPCR was performed on a StepOnePlus PCR System (Applied Biosystems) with TB Green Premix Ex Taq II (RR820A,

Takara Bio). Standard curves were generated using 0.5 ng, 1 ng, 2 ng, 4 ng and 8 ng of TIG-3 cell DNA for mtDNA amplification, and 1 ng, 2 ng, 4 ng, 8 ng and 16 ng for nuclear DNA amplification. The primer sequences were as follows:

- mtDNA, forward 5′-CTTCTGGCCACAGCACTTAAC-3′ and reverse 5′-GCTGGTGTTAGGGTTCTTTGTTTT-3′;
- β2M (nuclear DNA), forward 5′-GCTGGGTAGCTCTAAACAATG TATTCA-3′ and reverse 5′-CCATGTACTAACAAATGTCTAAAATGGT-3′.

RNA-seq analysis

RNA isolation was performed using TRIzol. Library preparation was performed using a TruSeq stranded mRNA Library Prep kit (Illumina) according to the manufacturer's instructions. Sequencing was performed on an Illumina NovaSeq 6000 sequencer (Illumina) in 101-base paired-end mode. Sequenced reads were mapped to the human reference genome sequences (hg19) using TopHat version 2.2.1. The number of fragments per kilobase of exon per million mapped fragments was calculated using Cufflinks version 2.2.1. The DEG and GO analysis was performed using the iDEP.96 webtool.

scRNA-seq analysis

scRNA-seq was performed using the Chromium Fixed RNA Kit, Human Transcriptome (10x Genomics). Approximately 10^6 fixed TIG-3 cells were hybridized with whole-transcriptome probe pairs for 18 h at 42 °C. Following post-hybridization washes, the cells were encapsulated into gel beads-in-emulsion (GEMs) using the Chromium X system. Within each GEM, ligated probe pairs were barcoded with 10x GEM barcodes and unique molecular identifiers, followed by heat denaturation and recovery. Barcoded products were pre-amplified and purified using SPRIselect beads. Final libraries were generated by sample index PCR with the Dual Index Kit TS Set A and purified by size selection. Library quality and size distribution were assessed using an Agilent Bioanalyzer, and concentrations were determined with the KAPA Library Quantification Kit (Roche). Libraries were sequenced on an Illumina NovaSeq X Plus platform with 151-base pair paired-end reads. Demultiplexing, alignment and gene expression quantification were performed using Cell Ranger v9.0.1 (10x Genomics), aligned to the human reference genome (GRCh38-2024-A). Filtered feature–barcode matrices were generated for downstream transcriptomic analyses.

OCR analysis

OCR was measured using a Seahorse XFe24 extracellular flux analyzer (Agilent Technologies). Cells ($0.5–1 \times 10^5$ per well) were seeded in XFe24 cell culture microplates (Agilent Technologies) and incubated with or without 7 μM BAY876 for 3 days. OCR was measured at 37 °C in Seahorse assay medium (5 mM HEPES, 10 mM glucose, and 10 mM pyruvate, pH 7.4). Each measurement cycle consisted of 3 min mixing, 30 s waiting and 3 min measurement. The first three cycles were used to assess basal respiration. Subsequently, 1.5 μM oligomycin, 1 μM FCCP, 0.5 μM rotenone and 0.5 μM antimycin A were sequentially injected, and OCR was recorded in IMR-90, TIG-3 and RPE-1 cells. After measurements, cells were stained with Hoechst 33342, and OCR values were normalized to viable cell numbers.

Statistics and reproducibility

All data are presented as the mean ± s.d. Statistical analyses were performed using GraphPad Prism software (version 10). Intergroup comparisons were performed using a two-tailed Student's or Welch's *t*-test, Kruskal–Wallis test or one-way ANOVA followed by Tukey's or Sidak's post hoc test, depending on the experimental design. Statistical details are provided in the figure legends. The criterion for statistical significance was set at $P < 0.05$. All experiments, except those shown in Fig. 2a–c and Extended Data Fig. 4a,b, were repeated at least two independent times with similar results. Data distribution was assumed to be normal, but this was not formally tested. Individual data points are shown in the figures. Data collection and analysis were not performed blind to the conditions of the experiments. Mice were randomly assigned to experimental groups before treatment using simple randomization, with group allocation stratified by genotype and/or treatment. No statistical methods were used to predetermine sample sizes for the lung metastasis and xenograft tumor assays, but the sample sizes used are similar to those reported in previous publications (refs. 14,46, respectively). No animals or data points were excluded from the analysis, except for aged mice bearing spontaneous cancers, which were excluded before analysis.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All data needed to understand and assess the conclusion of this study are included in the figures and Supplementary Information. scRNA-seq data (Fig. 2) and RNA-seq data (Extended Data Fig. 4 and Supplementary Fig. 2) have been deposited in the Gene Expression Omnibus under accession codes GSE313494, GSE313462 and GSE312784, respectively. Source data are provided with this paper. All other data supporting the findings of this study are available from the corresponding author upon reasonable request.

References

1. Munoz-Espin, D. & Serrano, M. Cellular senescence: from physiology to pathology. *Nat. Rev. Mol. Cell Biol.* **15**, 482–496 (2014).
2. He, S. & Sharpless, N. E. Senescence in health and disease. *Cell* **169**, 1000–1011 (2017).
3. Chan, A. S. L. & Narita, M. Short-term gain, long-term pain: the senescence life cycle and cancer. *Genes Dev.* **33**, 127–143 (2019).
4. Coppe, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS Biol.* **6**, 2853–2868 (2008).
5. Acosta, J. C. et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. *Cell* **133**, 1006–1018 (2008).
6. Kuilman, T. et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. *Cell* **133**, 1019–1031 (2008).
7. Baker, D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. *Nature* **479**, 232–236 (2011).
8. Baker, D. J. et al. Naturally occurring $p16^{Ink4a}$-positive cells shorten healthy lifespan. *Nature* **530**, 184–189 (2016).
9. de Magalhães, J. P. Cellular senescence in normal physiology. *Science* **384**, 1300–1301 (2024).
10. Chaib, S., Tchkonia, T. & Kirkland, J. L. Cellular senescence and senolytics: the path to the clinic. *Nat. Med.* **28**, 1556–1568 (2022).
11. Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. *Nat. Rev. Cancer* https://doi.org/10.1038/s41568-022-00450-9 (2022).
12. Di Micco, R., Krizhanovsky, V., Baker, D. & d'Adda di Fagagna, F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. *Nat. Rev. Mol. Cell Biol.* **22**, 75–95 (2021).
13. Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat. Med.* **22**, 78–83 (2016).
14. Wakita, M. et al. A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells. *Nat. Commun.* **11**, 1935 (2020).
15. Zhu, Y. et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell* **14**, 644–658 (2015).
16. Zhu, Y. et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-X-L inhibitors, A1331852 and A1155463. *Aging* **9**, 955–963 (2017).

17. Guerrero, A. et al. Cardiac glycosides are broad-spectrum senolytics. *Nat. Metab.* **1**, 1074–1088 (2019).
18. Triana-Martinez, F. et al. Identification and characterization of cardiac glycosides as senolytic compounds. *Nat. Commun.* **10**, 4731 (2019).
19. Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. *Nat. Commun.* **7**, 11190 (2016).
20. Xu, Q. et al. The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. *Nat. Metab.* **3**, 1706–1726 (2021).
21. Johmura, Y. et al. Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders. *Science* **371**, 265–270 (2021).
22. Go, S. et al. The senolytic drug JQ1 removes senescent cells via ferroptosis. *Tissue Eng. Regen. Med.* **18**, 841–850 (2021).
23. Limbad, C. et al. Senolysis induced by 25-hydroxycholesterol targets CRYAB in multiple cell types. *iScience* **25**, 103848 (2022).
24. McHugh, D. et al. COPI vesicle formation and *N*-myristoylation are targetable vulnerabilities of senescent cells. *Nat. Cell Biol.* **25**, 1804–1820 (2023).
25. Moaddel, R. et al. Identification of gingerenone A as a novel senolytic compound. *PLoS ONE* **17**, e0266135 (2022).
26. Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. *Exp. Cell. Res.* **25**, 585–621 (1961).
27. Bodnar, A. G. et al. Extension of life-span by introduction of telomerase into normal human cells. *Science* **279**, 349–352 (1998).
28. Ogrodnik, M. et al. Guidelines for minimal information on cellular senescence experimentation in vivo. *Cell* **187**, 4150–4175 (2024).
29. Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. *Aging Cell* **15**, 428–435 (2016).
30. Sakamaki, JI. et al. Bromodomain protein BRD_4 is a transcriptional repressor of autophagy and lysosomal function. *Mol. Cell* **66**, 517–532 (2017).
31. Aoyagi, Y. et al. Mitochondrial fragmentation triggers ineffective hematopoiesis in myelodysplastic syndromes. *Cancer Discov.* **12**, 250–269 (2022).
32. Nunnari, J. & Suomalainen, A. Mitochondria: in sickness and in health. *Cell* **148**, 1145–1159 (2012).
33. Colacurcio, D. J. & Nixon, R. A. Disorders of lysosomal acidification-the emerging role of v-ATPase in aging and neurodegenerative disease. *Ageing Res. Rev.* **32**, 75–88 (2016).
34. Correia-Melo, C. et al. Mitochondria are required for pro-ageing features of the senescent phenotype. *EMBO J.* **35**, 724–742 (2016).
35. Wiley, C. D. et al. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. *Cell Metab.* **23**, 303–314 (2016).
36. Kim, S. Y. et al. Epigenetic reader BRD4 (bromodomain-containing protein 4) governs nucleus-encoded mitochondrial transcriptome to regulate cardiac function. *Circulation* **142**, 2356–2370 (2020).
37. Stanlie, A., Yousif, A. S., Akiyama, H., Honjo, T. & Begum, N. A. Chromatin reader Brd4 functions in Ig class switching as a repair complex adaptor of nonhomologous end-joining. *Mol. Cell* **55**, 97–110 (2014).
38. Wisnovsky, S., Jean, S. R. & Kelley, S. O. Mitochondrial DNA repair and replication proteins revealed by targeted chemical probes. *Nat. Chem. Biol.* **12**, 567–573 (2016).
39. Trifunovic, A. et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature* **429**, 417–423 (2004).
40. Kujoth, G. C. et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. *Science* **309**, 481–484 (2005).
41. Liu, Y., Song, X. D., Liu, W., Zhang, T. Y. & Zuo, J. Glucose deprivation induces mitochondrial dysfunction and oxidative stress in PC12 cell line. *J. Cell. Mol. Med.* **7**, 49–56 (2003).
42. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* **324**, 1029–1033 (2009).
43. Khajah, M. A., Khushaish, S. & Luqmani, Y. A. Glucose deprivation reduces proliferation and motility, and enhances the anti-proliferative effects of paclitaxel and doxorubicin in breast cell lines in vitro. *PLoS ONE* **17**, e0272449 (2022).
44. Siebeneicher, H. et al. Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876. *ChemMedChem* **11**, 2261–2271 (2016).
45. James, E. L. et al. Senescent human fibroblasts show increased glycolysis and redox homeostasis with extracellular metabolomes that overlap with those of irreparable DNA damage, aging, and disease. *J. Proteome Res.* **14**, 1854–1871 (2015).
46. Kawaguchi, K., Komoda, K., Mikawa, R., Asai, A. & Sugimoto, M. Cellular senescence promotes cancer metastasis by enhancing soluble E-cadherin production. *iScience* **24**, 103022 (2021).
47. Allen, B. G. et al. Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. *Redox Biol.* **2**, 963–970 (2014).
48. Newman, J. C. & Verdin, E. Ketone bodies as signaling metabolites. *Trends Endocrinol. Metab.* **25**, 42–52 (2014).
49. Yang, J. et al. CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth. *Mol. Cancer* **22**, 92 (2023).
50. Mendt, M. & Cardier, J. E. Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis. *Melanoma Res.* **27**, 300–308 (2017).
51. Wei, S. J. et al. Ketogenic diet induces p53-dependent cellular senescence in multiple organs. *Sci. Adv.* **10**, eado1463 (2024).
52. Lebovitz, H. E. Diabetic ketoacidosis. *Lancet* **345**, 767–772 (1995).
53. van der Aart-van der Beek, A. B., de Boer, R. A. & Heerspink, H. J. L. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. *Nat. Rev. Nephrol.* **18**, 294–306 (2022).
54. Wechter, N. et al. Single-cell transcriptomic analysis uncovers diverse and dynamic senescent cell populations. *Aging* **15**, 2824–2851 (2023).
55. Tao, W., Yu, Z. & Han, J. J. Single-cell senescence identification reveals senescence heterogeneity, trajectory, and modulators. *Cell Metab.* **36**, 1126–1143 (2024).
56. Anerillas, C. et al. The YAP-TEAD complex promotes senescent cell survival by lowering endoplasmic reticulum stress. *Nat. Aging* **3**, 1237–1250 (2023).
57. Kang, T. W. et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. *Nature* **479**, 547–551 (2011).
58. Grosse, L. et al. Defined $p16^{high}$ senescent cell types are indispensable for mouse healthspan. *Cell Metab.* **32**, 87–99 (2020).
59. Yoshida, S. et al. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. *Nat. Commun.* **11**, 2482 (2020).
60. Suda, M. et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. *Nat. Aging* **1**, 1117–1126 (2021).
61. Chaib, S. et al. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. *Nat. Cancer* **5**, 448–462 (2024).
62. Majewska, J. et al. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells. *Nat. Cell Biol.* **26**, 1336–1345 (2024).
63. Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. *Nature* **583**, 127–132 (2020).
64. Fielder, E. P. et al. Mild uncoupling of mitochondria synergistically enhances senolytic specificity and sensitivity of BH3 mimetics. *Aging Biol.* **1**, 20240022 (2024).

65. Karnewar, S., Karnewar, V., Shankman, L. S. & Owens, G. K. Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality. *JCI Insight*. **9**, e173863 (2024).
66. Kawamoto, S. et al. Bacterial induction of B cell senescence promotes age-related changes in the gut microbiota. *Nat. Cell Biol.* **25**, 865–876 (2023).

Acknowledgements

We are grateful to K. Hagiwara and members of the laboratory of E.H. for the helpful discussions during manuscript preparation. We also thank Y. Wakabayashi for support in OCR analysis. This work was supported in part by grants from the Japan Agency of Medical Research and Development (AMED) under grant number JP25gm1710004h0004 (to E.H.), JP24ama221114h0003 (to E.H.), JP25zf0127008s0104 (to E.H.) and JP25gm1710013h0002 (to A.T.), the Japan Science and Technology Agency (JST) under grant number JPMJMS2022 (to E.H. and A.T.), Japan Society for the Promotion of Science (JSPS) under grant numbers JP25H00443 (to E.H.), JP25K14865 (to M.W.) and JP25KJ1722 (to J.H.P.), Ministry of Education, Culture, Sports, Science and Technology (MEXT) under grant number JPMXP1323015484 (to E.H.), The University of Osaka OU Master Plan Implementation Project (to E.H.), Princess Takamatsu Cancer Research Fund (to M.W.) and the Mitsubishi Foundation (to E.H.). Some of the aged mice were provided by the Foundation for Biomedical Research and Innovation at Kobe through the National BioResource Project of the MEXT, Japan (to M.W.).

Author contributions

M.W. and E.H. designed the study, analyzed the data and wrote the paper. M.W. performed the majority of the experiments. K.I., D.S., H.M., T.M., S.S. and X.Z. validated the reproducibility of the data. K.F. contributed to immunofluorescence analysis. D.M. performed RNA-seq analysis. J.H.P. conducted bioinformatic analyses. E.O. and N.I. contributed to mitochondrial analyses. A.T. and H.K. contributed to data analysis. E.H. supervised the project. All authors read and approved the final paper.

Competing interests

The authors declare no competing interests.

Additional information

Extended data is available for this paper at https://doi.org/10.1038/s43587-025-01057-z.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s43587-025-01057-z.

Correspondence and requests for materials should be addressed to Eiji Hara.

Peer review information *Nature Aging* thanks Carlos Anerillas, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

https://doi.org/10.1038/s43587-025-01057-z



Extended Data Fig. 1 | Comparative analysis of the activity and specificity of reported senolytic drugs in fibroblasts. Early-passage pre-senescent (control) IMR-90 cells were rendered senescent by serial passage (Rep-Sen). Senescent and control cells were treated with the indicated compounds at the concentrations shown on the right for 3 days. Relative cell numbers were counted throughout the experiments. The Senolytic Specificity Index (SSI) was calculated as: SSI = (% reduction of senescent cells at day 3 relative to day 0) / (% reduction of control cells at day 2 relative to untreated control cells). If the reduction of control cells at day 2 was <1%, the denominator was set to 1 and the result denoted as SSI > value. For each compound, the SSI value at the concentration yielding the highest index is shown at the top of the panel. Error bars represent mean ± s.d. Experiments were independently repeated at least once to confirm reproducibility.

https://doi.org/10.1038/s43587-025-01057-z



Extended Data Fig. 2 | Comparative analysis of the activity and specificity of reported senolytic drugs in epithelial cell. Pre-senescent (control) RPE-1 cells were rendered senescent by treatment with 150 ng/ml doxorubicin for 10 days (DXR-Sen). Senescent and control cells were treated with the indicated compounds at the concentrations shown on the right for 3 days. Relative cell numbers were counted throughout the experiments. The Senolytic Specificity Index (SSI) was calculated as: SSI = (% reduction of senescent cells at day 3 relative to day 0) / (% reduction of control cells at day 2 relative to untreated control cells). If the reduction of control cells at day 2 was <1%, the denominator was set to 1 and the result denoted as SSI > value. For each compound, the SSI value at the concentration yielding the highest index is shown at the top of the panel. Error bars represent mean ± s.d. Experiments were independently repeated at least once to confirm reproducibility.

https://doi.org/10.1038/s43587-025-01057-z



Extended Data Fig. 3 | Comparison of apoptosis-inducing activity in control cells of reported senolytic drugs. Early-passage pre-senescent (control) IMR-90 (**a**) and RPE-1 (**b**) cells were incubated with each compound at the concentration yielding the highest SSI value (see Extended Data Fig. 1 and 2) for 3 days. Apoptotic response was assessed by Annexin V staining, and nuclei were counterstained with DAPI. Representative images from two independent experiments are shown. Scale bars, 50 µm. Histograms show the percentage of Annexin V–positive cells, quantified from five independently cultured dishes per condition. Data are presented as mean ± s.d. Experiments were independently repeated at least once to confirm reproducibility.

https://doi.org/10.1038/s43587-025-01057-z



Extended Data Fig. 4 | See next page for caption.

https://doi.org/10.1038/s43587-025-01057-z

Extended Data Fig. 4 | Characteristics of senescent cells resistant to ABT263 and ARV825. a,b, Hallmark gene set enrichment analysis (**a**) and Gene Ontology pathway analysis (**b**) of differentially expressed genes identified by RNA-seq, comparing doxorubicin-induced senescent (DXR-Sen) TIG-3 cells treated with or without ABT263 or ARV825 for 7 days. *P* values were adjusted for multiple comparisons using the Benjamini–Hochberg method to control the false discovery rate (FDR). Terms with an adjusted P-value (FDR) less than 0.05 were considered statistically significant. **c**–**e**, Relative expression levels of SASP factors (CXCL2, CXCL3, CXCL5, CCL20 and MMP3 mRNA by RT–qPCR, **c**; protein by immunofluorescence, **d**) and oxidoreductase activity–associated genes (AKR1C1, AKR1C2 and AKR1C3 mRNA by RT–qPCR, **e**) in control pre-senescent HDFs and DXR-induced senescent HDFs with or without ABT263 or ARV825 treatment. For **c** and **e**, biological replicate data are shown. In each independent experiment (five for panel **c** and four for panel **e**), three technical measurements were obtained and averaged to generate a single biological replicate. Data are presented as mean ± s.d. Statistical significance was assessed by two-sided Student's *t*-test (**c, e**). For **d**, immunofluorescence intensities were quantified at the single-cell level; 83 cells were analyzed per group. Each dot represents an individual cell. Although data shown are from one representative experiment, experiments were independently repeated at least once to confirm reproducibility. Nuclei were counterstained with DAPI (blue). Statistical significance was assessed by two-sided Student's *t*-test.

https://doi.org/10.1038/s43587-025-01057-z



Extended Data Fig. 5 | See next page for caption.

https://doi.org/10.1038/s43587-025-01057-z

Extended Data Fig. 5 | Time-course analysis of mitochondrial membrane potential and ROS during treatment with ABT263 and ARV825 in senescent cells. a, b, Early-passage TIG-3 cells were rendered senescent by treatment with 250 ng/ml doxorubicin for 10 days. Cells were then incubated with ABT263 (0.5 μM) or ARV825 (25 nM) for the indicated durations and subjected to MT-1 staining to assess mitochondrial membrane potential (**a**) or to CellROX staining to measure intracellular ROS levels (**b**). Nuclei were counterstained with DAPI. Scale bars, 10 μm. Histograms below each image show quantification. At least 50 cells were scored per group. **c**, Early-passage TIG-3 cells (control cells) and DXR-induced senescent TIG-3 cells (DXR-Sen cells) were treated with ABT263 (0.5 μM) or ARV825 (25 nM) with or without N-acetyl-L-cysteine (NAC; 0.3 mM) for 3 days. Relative cell numbers were counted throughout the experiments. Error bars represent mean ± s.d. Statistical significance was assessed by Kruskal-Wallis test (**a, b**), or two-sided Welch's t-test (**c**). Representative data from three independent experiments are shown.

https://doi.org/10.1038/s43587-025-01057-z



Extended Data Fig. 6 | See next page for caption.

https://doi.org/10.1038/s43587-025-01057-z

Extended Data Fig. 6 | V-ATPase plays a key role in senolysis resistance. **a**–**c**, Early-passage TIG-3 cells (control cells) or DXR-Sen TIG-3 cells were transfected twice, at 3-day intervals, with validated siRNAs targeting *ATP6V0E1* or a control siRNA. Cells were analysed by western blotting to confirm ATP6V0E1 depletion (**a**), then treated with or without ABT263 or ARV825 for 3 days and subjected to MT-1 staining to assess mitochondrial membrane potential at day 2 (**b**) or relative cell number analysis (**c**). **d, e**, Control or DXR-Sen TIG-3 cells were treated with or without ABT263 or ARV825 in the presence or absence of 1 μM EN6 (a V-ATPase activator) for 3 days and subjected to MT-1 staining to assess mitochondrial membrane potential at day 2 (**d**) or relative cell number analysis (**e**). 51 cells (**b**) and 53 cells (**d**) were scored per group. Data are presented as mean ± s.d. (**b**–**e**). Statistical significance was determined by one-way ANOVA followed by Sidak's test (**b**, **d**), or two-sided Welch's t-test (**c**, **e**). Scale bars, 10 μm (**b, d**). Experiments were independently repeated at least once to confirm reproducibility.

https://doi.org/10.1038/s43587-025-01057-z



Extended Data Fig. 7 | Removal of mitochondria from senescent cells confers resistance to ABT263- and ARV825-induced senolysis. a, Experimental timeline. DXR-induced senescent TIG-3 cells were incubated with 100 ng/ml ethidium bromide (EtBr) and 50 μg/ml uridine (Urd) for 2 months to generate ρ^0 cells. **b**, Cells were subjected to western blotting with the indicated antibodies. **c**, mtDNA copy number analysis. **d**, Relative cell numbers after treatment with ABT263 or ARV825 for 3 days. Data are presented as mean ± s.d. Statistical significance was assessed by two-sided Student's t-test (**c**) or two-sided Welch's t-test (**d**). Although data shown are from technical replicates, experiments were independently repeated at least once to confirm reproducibility.

https://doi.org/10.1038/s43587-025-01057-z



Extended Data Fig. 8 | ARV825 targets mitochondria through the BRD4–XRCC4 axis. a, DXR-induced senescent TIG-3 cells were treated with ARV825 (25 nM) for 3 days and analysed by western blotting with the indicated antibodies. **b, c**, Early-passage (control) or DXR-induced senescent (DXR-Sen) TIG-3 cells were transfected twice at 3-day intervals with validated siRNAs against BRD4, or a control siRNA. Cells were subjected to western blotting (**b**) or MT-1 staining for mitochondrial membrane potential (**c**), β-actin was used as a loading control (**b**). Nuclei were counterstained with DAPI and histograms show single-cell quantification; 60 cells were analysed per group (**c**). **d**, DXR-induced senescent TIG-3 cells were analysed by western blotting after immunoprecipitation with the antibodies indicated at the top (IP). **e**, DXR-induced senescent TIG-3 cells were subjected to immunofluorescence staining for XRCC4 and MitoTracker; nuclei were counterstained with DAPI. **f-k**, Control and DXR-induced senescent TIG-3 cells were transfected twice at 3-day intervals with siRNAs against XRCC4, LIG3, or control siRNA. Cells were analysed by western blotting (**f, j**), cell survival assays (**g, k**), MT-1 staining for mitochondrial membrane potential (**h**), or CellROX staining for ROS levels (**i**). Nuclei were counterstained with DAPI. For **h** and **i**, histograms show single-cell quantification; 96 cells (control) and 51 cells (DXR-Sen) were analysed per group in **h**, and 58 cells per group in **i**. β-actin was used as a loading control (**f, j**). Data are presented as mean ± s.d. Statistical significance was assessed by two-sided Student's or Welch's t-test (**c, g, h, i, k**). Scale bars, 5 μm (**b, c, d, h**). Although data shown are from technical replicates (**c, g, h, i, k**), experiments were independently repeated at least once to confirm reproducibility.

https://doi.org/10.1038/s43587-025-01057-z



Extended Data Fig. 9 | See next page for caption.

https://doi.org/10.1038/s43587-025-01057-z

Extended Data Fig. 9 | Imposing mitochondrial stress enhances the senolytic efficacy of ABT263 and ARV825. Early-passage pre-senescent (control) or DXR-induced senescent (DXR-Sen) TIG-3 cells were transfected twice, at 3-day intervals, with two different validated siRNAs targeting *Polg* or a control siRNA. **a**, Experimental timeline. **b, c**, On day 3, cells were analysed by western blotting to confirm Polg knockdown efficiency (**b**) or by mtDNA copy number analysis (**c**). **d**–**f**, Remaining cells were further treated with ABT263 or ARV825 for 3 additional days and, 2 days later, subjected to MT-1 staining to assess mitochondrial membrane potential (**d**) or CellROX staining to detect ROS levels (**e**). Relative cell numbers were monitored throughout the experiments (**f**). Nuclei were counterstained with DAPI and histograms show single-cell quantification; 51 cells (**d**) and 60 cells (**e**) were scored per group. Data are presented as mean ± s.d. (**c**–**f**). Statistical significance was assessed by one-way ANOVA followed by Tukey's or Sidak's test (**c, d, e**), or two-sided Welch's t-test (**f**). Scale bars, 10 µm (**d, e**). Representative results from two independent experiments are shown.

https://doi.org/10.1038/s43587-025-01057-z



Extended Data Fig. 10 | Ketogenic diet feeding or SGLT2 inhibition enhances the senolytic efficacy of ABT263 and ARV825 in mice. a and **b**, Mice described in Fig. 4a were euthanized at week 100, and tumour-free areas of the lungs were collected and subjected to the immunofluorescence analysis of $p16^{INK4a}$-positive (**a**) or $p21^{WAF1/CIP1}$-positive (**b**) but Ki67-negative cells (4 fields per mouse, 6 mice per group). **c** and **d**, Mice described in Fig. 4f were euthanized and serial sections of xenograft tumours were analysed by dihydroethidium (DHE) staining for ROS (**c**), or TUNEL staining (**d**). Nuclei were counterstained with DAPI. Enlarged views of regions outlined with yellow dotted lines are shown in the lower left corners; histograms to the right show the percentages of positive cells, quantified from 4 fields per mouse across 5 mice per group. Data are presented as mean ± s.d. (**a**–**d**). Statistical significance was assessed by two-sided Welch's t-test (**a**-**d**). Scale bars, 10 μm (**a**-**d**). Although data shown are from technical replicates, experiments were independently repeated at least once to confirm reproducibility.

nature portfolio

Corresponding author(s): Eiji Hara

Last updated by author(s): Dec 19, 2025

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed	
☐	☒	The exact sample size (*n*) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒	The statistical test(s) used AND whether they are one- or two-sided *Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
☒	☐	A description of all covariates tested
☒	☐	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒	For null hypothesis testing, the test statistic (e.g. *F*, *t*, *r*) with confidence intervals, effect sizes, degrees of freedom and *P* value noted *Give P values as exact values whenever suitable.*
☒	☐	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐	Estimates of effect sizes (e.g. Cohen's *d*, Pearson's *r*), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection	Western blotting: Amersham ImageQuant 800 (Cytiva) Histological and fluorescence images data: All-in-One Fluorescence Microscope (BZ-710; Keyence) Quantitative real-time RT-PCR data: StepOnePlus PCR System (Applied Biosystems) OCR : Seahorse XFe24 extracellular flux analyzer (Seahorse Bioscience) Sequence data: Illumina NovaSeq 6000 sequencer (Illumina), illumina NovaSeq X Plus (Illumina)
Data analysis	Histological and fluorescence data analysis: imageJ 2.14.0/1.54f Statistical analysis: GraphPad Prism 10.2.3 Sequence data analysis: TopHat ver. 2.2.1, Cufflinks version 2.2.1, iDEP.96 ImageJ (version 1.54) Single cell RNA sequence analysis: Seurat (version 5) Statistical analysis: GraphPad Prism 10. 4.2

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data needed to understand and assess the conclusion of this study are included in the figures and supplementary materials. scRNA-seq data (Fig. 2) and RNA-seq data (Extended Data Fig. 4 and Supplementary Fig. 2) have been deposited in the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) with the accession codes GSE313494, GSE313462 and GSE312784, respectively. Source data are provided with this paper. All other data supporting the findings of this study are available from the corresponding author upon reasonable request.

Research involving human participants, their data, or biological material

Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation), and sexual orientation and race, ethnicity and racism.

Reporting on sex and gender	N/A
Reporting on race, ethnicity, or other socially relevant groupings	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The sample size used in this study was determined based on the experience with the preliminary in vitro and in vivo studies, and the need to have sufficient statistical power.
Data exclusions	No animals or data points were excluded from the analysis, except for aged mice bearing spontaneous cancer.
Replication	All experiments were repeated at least two or three times and were confirmed to be reproducible.
Randomization	For in vitro studies, cells were seeded and randomly allocated to experimental groups. For in vivo studies, mice were randomly assigned to experimental groups prior to treatment using simple randomization, with group allocation stratified by genotype and/or treatment.
Blinding	Blinding was not performed during data collection and analysis because the experiments were conducted by a single researcher.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☐	☒ Antibodies
☐	☒ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☐	☒ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging

Antibodies

Antibodies used

Western blot:
β-actin (1:2000; A5316; Sigma-Aldrich), LaminB1 (1:1000; ab16048; Abcam), p16 (1:1000; sc-56330; Santa cruz), p21 (1:1000; 2947; Cell Signaling), XRCC4 (1:1000; sc-271087; Santa Cruz), LIG3 (1:1000; sc-135883; Santa Cruz), POLG (1:1000; ab128899; abcam), ATP6V0E1 (1:1,000; PA5-1114887; Thermo Fisher Scientific), BRD4 (1:1,000; 13440; Cell Signaling Technology), Anti-rabbit IgG, HRP-linked Antibody (1:2000; 7074; Cell signaling), and Anti-mouse IgG, HRP-linked Antibody (1:2000; 7076; Cell Signaling)

IP:
control IgG (5414; Cell Signaling Technology)

IHC:
p16 (1:1000; ab211542; Abcam), p21 (1:1000; ab188224; Abcam), Ki67 (1:1000; 14-5698-82; ThermoFisher Scientific),53BP1 (1:1000; NB100-304; Novus Biologicals), ImmPRESS Polymer Anti-Rabbit IgG (MP-7401; Vector), and Alexa Fluor™ 488 Anti-rat IgG (1:2000, A-21208, Thermo Fisher Scientific)

ICC:
CXCL2 (1:50, AF-452-NA, R&D Systems), GROα/β/γ (1:50, sc-365870, Santa Cruz), CXCL5 (1:50, AF254, R&D Systems), CCL20 (1:50, AF360, R&D Systems) MMP3 (1:50, 66338-1-Ig, Proteintech), Alexa Fluor™ 488 Donkey anti-Mouse IgG (1:2000, A21202, Thermo Fisher Scientific), Alexa Fluor™ 555 Donkey anti-Mouse IgG (1:2000, A-32773, Thermo Fisher Scientific), Alexa Fluor™ 555 Donkey anti-goat IgG (1:2000, A-32816, Thermo Fisher Scientific)

Validation

All commercially available antibodies have been validated by the manufacturers. Data sheet is available from the following manufacturer's weblinks.

Western blot:
β-actin : https://www.sigmaaldrich.com/JP/ja/product/sigma/a5316?srsltid=AfmBOorY8h74yXTJtzgKDNbtfIPvCW5c8KrZZRM1SBeujhDlSfWR5ktD
LaminB1 : https://www.abcam.co.jp/products/primary-antibodies/lamin-b1-antibody-nuclear-envelope-marker-ab16048.html
p16: https://www.scbt.com/ja/p/p16-antibody-jc8?srsltid=AfmBOoph-OnEAQq0qAIHQYDQ5ourGofAzf2fLXYUEn6WQlSZZ29KLXnn
p21: https://www.cellsignal.jp/products/primary-antibodies/p21-waf1-cip1-12d1-rabbit-mab/2947
XRCC4: https://www.scbt.com/ja/p/xrcc4-antibody-c-4?srsltid=AfmBOorQSKxHqdq0-iTYC0JCQHxK5L0GPsDXin7N09gLKcYQfZj1NmcH
LIG3: https://www.scbt.com/ja/p/dna-ligase-iii-antibody-7?srsltid=AfmBOopszN-ocCPNWo66ciqKtO8UI6X9U7Jn-4FkbLgof4SNTaA7sb9B
POLG: https://www.abcam.co.jp/products/primary-antibodies/polg-antibody-epr7296-ab128899.html
ATP6V0E1: https://www.thermofisher.com/antibody/product/V-ATPase-E1-Antibody-Polyclonal/PA5-114887
BRD4: https://www.cellsignal.com/products/primary-antibodies/brd4-e2a7x-rabbit-mab/13440?srsltid=AfmBOoonlfTy1QL9TcQ86aAPdL2Yg_t-hlELCPMpkPBBu1bxdBueaEX5
Anti-rabbit IgG, HRP-linked Antibody: https://www.cellsignal.jp/products/secondary-antibodies/anti-rabbit-igg-hrp-linked-antibody/7074
Anti-mouse IgG, HRP-linked Antibody: https://www.cellsignal.jp/products/secondary-antibodies/anti-mouse-igg-hrp-linked-antibody/7076

IP:
control IgG: https://www.cellsignal.com/products/primary-antibodies/mouse-g3a1-mab-igg1-isotype-control/5415

IHC:
p16: https://www.abcam.co.jp/products/primary-antibodies/cdkn2ap16ink4a-antibody-epr20418-ab211542.html
p21: https://www.abcam.co.jp/products/primary-antibodies/p21-antibody-epr18021-ab188224.html
Ki67: https://www.thermofisher.com/antibody/product/Ki-67-Antibody-clone-SolA15-Monoclonal/14-5698-82
53BP1: https://www.novusbio.com/products/53bp1-antibody_nb100-304?srsltid=AfmBOopuu3IR17v9pK6jzOVT6b6Cnq6cCDlx-ZBw2AOi89bv1sBuefL1
ImmPRESS Polymer Anti-Rabbit IgG: https://vectorlabs.com/products/immpress-hrp-horse-anti-rabbit-igg/?srsltid=AfmBOoqznGISOHNSImvu6-X2u82dDeAmeLS2yV1U2woUfgDohcaMFPcN
Alexa Fluor™ 488 Anti-rat IgG : https://www.thermofisher.com/antibody/product/Donkey-anti-Rat-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21208

ICC:
CXCL2: https://www.rndsystems.com/products/mouse-cxcl2-mip-2-antibody_af-452-na
GROα/β/γ: https://www.scbt.com/ja/p/groalpha-beta-gamma-antibody-a-6?

srsltid=AfmBOooPSAlotjTvk0QZNtGXn8dIAYIO6ZOn3unaY1ZQJYriVHExxdW0
CXCL5: https://www.rndsystems.com/products/human-cxcl5-ena-78-antibody_af254
CCL20: https://www.rndsystems.com/products/human-ccl20-mip-3alpha-antibody_af360
MMP3: https://www.ptglab.com/products/MMP3-Antibody-66338-1-Ig.htm?
srsltid=AfmBOoonvxMYu70to13JSW7ubCna94_ZHwhfbRzR5m0HvtdieLxcGbv_
Alexa Fluor™ 488 Donkey anti-Mouse IgG: https://www.thermofisher.com/antibody/product/Donkey-anti-Mouse-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21202
Alexa Fluor™ 555 Donkey anti-Mouse IgG : https://www.thermofisher.com/antibody/product/Donkey-anti-Mouse-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A32773
Alexa Fluor™ 555 Donkey anti-goat IgG: https://www.thermofisher.com/antibody/product/Donkey-anti-Goat-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A32816

Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research

Cell line source(s)	Human diploid fibroblasts, IMR-90 cells, TIG-1 cells , TIG-3 cells, and B16BL6 cells were obtained from Public Bioresouces Bank. Human retinal pigment epithelial (HRPE) cells and HCT116 cells were purchased from Lonza Inc. and ATCC., respectively
Authentication	Cell line used in this studies were obtained from public bioresources bank or Company.
Mycoplasma contamination	All cell were tested to be free of mycoplasma cantamination
Commonly misidentified lines (See ICLAC register)	N/A

Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

Laboratory animals	87 week-old male C57BL/6J mice and 6–8-week-old Nude (nu/nu) mice were maintained in a pathogen-free environment and housed in transparent cages, in groups of seven animals per cage at 23°C±2C and 55%±15% humidity on a 12-h light–dark cycle.
Wild animals	The study does not involve wild animals.
Reporting on sex	The study use male mouse.
Field-collected samples	The study does not involve field collected animals.
Ethics oversight	All animal experiments were approved by the Animal Research Committee of the Research Institute for Microbial Diseases, The University of Osaka.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Seed stocks	N/A
Novel plant genotypes	N/A
Authentication	N/A